AVAH
Aveanna Healthcare Holdings Inc.
AVAH's outlook is improving, though it still trails on the overall score.
LLY
Eli Lilly and Company
LLY has the edge over AVAH overall, supported by lower modeled downside and stronger fundamentals.
AVAH Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Healthy | |
| Under pressure |
AVAH's revenue, profitability and cash flow are currently healthy, but its balance sheet is under pressure.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
AVAH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 6.6x | $9.24 | -25% |
| Current | 8.7x | $12.24 | — |
| Forward | 14x | $12.24 | — |
| Fair | 21x | $29.51 | +141% |
| Expensive | 108x | $151 | +1130% |
Historical ranges are pointers, not guarantees.
AVAH has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
AVAH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for AVAH, with profitability improving.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over AVAH on the outlook, with more favorable valuation expectations.
AVAH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.88 | -37% |
| Q3 2026 | $1.40 | +278% |
| Q2 2026 | $1.26 | +1300% |
| Q1 2026 | $1.21 | +3933% |
| Q4 2025 | $1.05 | +$1.11 |
| Q3 2025 | $0.37 | +$0.71 |
| Q2 2025 | $0.09 | +$0.75 |
| Q1 2025 | $0.03 | +$0.63 |
| Q4 2024 | -$0.06 | +$0.65 |
AVAH's earnings per share have climbed steadily: $1.40 over the past year, about four times what it earned the year before, and higher year over year for 14 quarters in a row.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY's earnings per share have climbed steadily: $30.81 over the past year, up 51% from the year before, and higher year over year for 11 quarters in a row.
AVAH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $695.5M | +12% |
| Q2 2026 | $670.5M | +14% |
| Q1 2026 | $647.9M | +16% |
| Q4 2025 | $662.5M | +27% |
| Q3 2025 | $621.9M | +22% |
| Q2 2025 | $589.6M | +17% |
| Q1 2025 | $559.2M | +14% |
| Q4 2024 | $519.9M | +8.6% |
AVAH's revenue has grown year over year for 19 quarters in a row: $696M last quarter, up 12% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 12% | +3.4 points |
| Q2 2026 | 12% | -1.7 points |
| Q1 2026 | 11% | +1.4 points |
| Q4 2025 | 11% | +1.9 points |
| Q3 2025 | 8.6% | +1.9 points |
| Q2 2025 | 14% | +6.2 points |
| Q1 2025 | 9.3% | +4.6 points |
| Q4 2024 | 8.8% | +2.7 points |
AVAH's operating margin was 12% last quarter, up 3.4 points from the same quarter a year ago, near the top of its range since 2020.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over AVAH on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over AVAH on profitability, with a higher operating margin.
AVAH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $72.2M | +118% |
| Q2 2026 | $80.9M | +57% |
| Q1 2026 | $4.3M | +$13M |
| Q4 2025 | $49.7M | +271% |
| Q3 2025 | $33.2M | +13% |
| Q2 2025 | $51.6M | +2751% |
| Q1 2025 | -$8.6M | +$3.3M |
| Q4 2024 | $13.4M | +$16.4M |
AVAH has the edge over LLY on cash flow, with more consistent year-over-year improvement.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
AVAH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.9% | +4.4M shares |
| 1 year | +3.1% | +7M shares |
| 3 years | +21% | +40.1M shares |
| 5 years | +29% | +51.5M shares |
| Available history | +27% | +49.1M shares |
AVAH has 229M diluted shares, up 3.1% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over AVAH on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
AVAH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 3.5x | Elevated |
| Q2 2026 | 4.2x | High |
| Q1 2026 | 3.9x | Elevated |
| Q4 2025 | 4.1x | High |
| Q3 2025 | 4.8x | High |
| Q2 2025 | 5.3x | High |
| Q1 2025 | 6.7x | High |
| Q4 2024 | 8.0x | High |
AVAH's net debt is about 3.5 years of its operating earnings (EBITDA), down from 4.8 years a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY has the edge over AVAH on leverage, with a lower net debt burden relative to earnings.
AVAH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.6 | Neutral |
| Stochastic | 69.3 | Neutral |
AVAH's weekly RSI is 58 (neutral) and its Stochastic is 69 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
AVAH PE vs Healthcare Sector
| Metric | AVAH | Sector median | Relative |
|---|---|---|---|
| PE | 8.7x | 26x | 66% below |
| PE % | 27 | 36 | 9 pts below |
AVAH has the edge over LLY on valuation relative to its sector.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
AVAH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $12.7 | 3.6% below |
| 20 week MA | $11.9 | 2.6% above |
| 50 week MA | $9.34 | 31% above |
| 100 week MA | $7.66 | 60% above |
| 200 week MA | $5.12 | 139% above |
AVAH's trend is up, with a small recent dip: it's below only its 8-week average, and 139% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over AVAH on trend strength, trading above more of its moving averages.
AVAH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $11.7 | $7.07 | -39% |
| 2022 | $7.07 | $0.77 | -89% |
| 2023 | $0.77 | $2.68 | +248% |
| 2024 | $2.68 | $4.66 | +74% |
| 2025 | $4.66 | $8.62 | +85% |
| 2026 YTD | $8.62 | $12.2 | +42% |
AVAH has the edge over LLY on returns for 2026, with the stronger performance.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.